Search results for : abt-263 - Cancerrxgene - Genomics of Drug Sensitivity in Cancer

Name	Synonyms	Targets	Target Pathway	PubCHEM	Datatset	Sample size	Screening site
Navitoclax	ABT-263, ABT263, ABT 263	BCL2, BCL-XL, BCL-W	Apoptosis regulation	24978538	GDSC1	928	SANGER
Navitoclax	ABT-263, ABT263, ABT 263	BCL2, BCL-XL, BCL-W	Apoptosis regulation	24978538	GDSC2	967	SANGER

The Genomics of Drug Sensitivity in Cancer Project is a collaboration between the Cancer Genome Project at the Wellcome Sanger Institute (UK) and the Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center (USA). This work is funded by Wellcome.

Users have a non-exclusive, non-transferable right to use data files for internal proprietary research and educational purposes, including target, biomarker and drug discovery. Excluded from this licence are use of the data (in whole or any significant part) for resale either alone or in combination with additional data/product offerings, or for provision of commercial services.
Please note: The data files are experimental and academic in nature and are not licensed or certified by any regulatory body. Genome Research Limited provides access to data files on an “as is” basis and excludes all warranties of any kind (express or implied).

Genomics of Drug Sensitivity in Cancer

Search Results for: abt-263